• Explore /
  • Poster
  • / Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phase Ib study.

Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phase Ib study.

Abstract Poster

Authors

null

Wen Zhang

Department of Medical oncology, Cancer Hospital, CAMS, Beijing, China

Wen Zhang , Xinyu Bi , Yongkun Sun , Yue Yu , Jian-guo Zhou , Huiying Zeng , Fan Wu , Yang Luo , Yong Yang , Mingxia Chen , Yan Wang , Hui Zhou , Jianqiang Cai , Hong Zhao , Aiping Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT04072679

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3079)

DOI

10.1200/JCO.2020.38.15_suppl.3079

Abstract #

3079

Poster Bd #

143

Abstract Disclosures

Similar Posters

First Author: Ming Liu

First Author: Leijuan Gan

First Author: Jaekyung Cheon

First Author: Jian Zhou